Oncology Today with Dr Neil Love cover art

All Episodes

Oncology Today with Dr Neil Love — 480 episodes

#
Title
1

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances

2

Metastatic Bladder Cancer — Rapid Case Review Issue 5

3

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

4

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

5

Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies

6

Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

7

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

8

For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

9

Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

10

Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

11

Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

12

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR

13

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress

14

TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting

15

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3

16

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2

17

For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress

18

Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

19

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1

20

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2

21

Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

22

For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress

23

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

24

EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

25

Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

26

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

27

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

28

Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

29

HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review

30

Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

31

Endometrial Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer

32

Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft

33

Endometrial Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer

34

Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

35

Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

36

Endometrial Cancer — An Interview with Dr Floor J Backes

37

For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress

38

Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay

39

For Oncology Nurses: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress

40

Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit

41

HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit

42

Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit

43

Desmoid Tumors and Soft Tissue Sarcoma — Fifth Annual National General Medical Oncology Summit

44

EGFR-Mutated Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit

45

Metastatic Triple-Negative Breast Cancer — What Clinicians Want to Know

46

Urothelial Bladder Cancer — Year in Review Series on Relevant New Datasets and Advances

47

Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit

48

For Oncology Nurses: Endometrial Cancer — Proceedings from the 2026 Annual ONS Congress

49

HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit

50

Prostate Cancer — Fifth Annual National General Medical Oncology Summit

51

Colorectal Cancer — Fifth Annual National General Medical Oncology Summit

52

Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit

53

Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper

54

Ovarian Cancer — Fifth Annual National General Medical Oncology Summit

55

Gastroesophageal Cancers — Fifth Annual National General Medical Oncology Summit

56

Multiple Myeloma — Fifth Annual National General Medical Oncology Summit

57

First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck

58

Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit

59

HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer

60

Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit

61

Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting

62

Pancreatic Cancer — Fifth Annual National General Medical Oncology Summit

63

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit

64

Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting

65

HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy

66

Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

67

Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

68

Antibody-Drug Conjugates in Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer

69

Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper

70

Colorectal Cancer — Year in Review Series on Relevant New Datasets and Advances

71

Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

72

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances

73

Ovarian Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer

74

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

75

PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida

76

Immunotherapy for Endometrial Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer

77

Oncology Nursing Update: Nonmelanoma Skin Cancers — An Interview with Dr Nikhil Khushalani

78

Localized Colorectal Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

79

Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

80

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

81

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

82

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

83

Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

84

Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

85

HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making

86

Metastatic Bladder Cancer — Rapid Case Review Issue 4

87

ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy

88

Localized Colorectal Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

89

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

90

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

91

Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan

92

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

93

Nonmelanoma Skin Cancers — A Roundtable Discussion on the Multidisciplinary Management of Cutaneous Squamous Cell and Basal Cell Carcinomas

94

Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review

95

AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium

96

Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway

97

Metastatic Bladder Cancer — Rapid Case Review Issue 3

98

Localized Colorectal Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

99

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium

100

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

101

CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson

102

Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review

103

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

104

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

105

Desmoid Tumors — Microlearning Activity 1 with Dr Ravin Ratan

106

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

107

CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah

108

Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting

109

Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review

110

Ovarian Cancer — Year in Review Series on Relevant New Datasets and Advances

111

Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review

112

Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

113

Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy

114

Colorectal Cancer — A Roundtable Discussion on the Use of Molecular Residual Disease Analysis

115

Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review

116

Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators

117

Metastatic Bladder Cancer — Rapid Case Review Issue 2

118

Gynecologic Cancers — Highlights from the 2025 ESMO Annual Meeting

119

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review

120

Squamous Cell Carcinoma of the Anal Canal — An Interview with Dr Marwan Fakih

121

Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review

122

Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore

123

Localized Colorectal Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium

124

Immune Thrombocytopenia — ASH 2025 Review

125

Urothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 Review

126

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review

127

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium

128

Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review

129

HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium

130

Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

131

Metastatic Bladder Cancer — Rapid Case Review Issue 1

132

Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review

133

Relapsed/Refractory Multiple Myeloma — ASH 2025 Review

134

HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

135

Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

136

Colorectal Cancer — 5-Minute Journal Club Issue 2 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

137

Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

138

Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

139

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

140

Colorectal Cancer — 5-Minute Journal Club Issue 1 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

141

Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

142

Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases

143

Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2

144

Urothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual Meeting

145

Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy

146

Gastroesophageal Cancers — Proceedings from a Symposium Held in Partnership with the American Oncology Network

147

Ovarian Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network

148

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network

149

Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network

150

CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients

151

HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach

152

Breast Cancer — Highlights from the 2025 ESMO Annual Meeting

153

Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

154

Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning

155

Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

156

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

157

Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

158

HER2-Positive Gastrointestinal Cancers — Clinical Investigator Perspectives on Actual Patient Cases

159

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

160

Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy

161

ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs

162

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

163

Colorectal Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

164

Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

165

Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

166

Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

167

Endometrial Cancer — Clinical Investigator Perspectives on Actual Patient Cases

168

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

169

Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis

170

Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

171

Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA

172

Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates

173

Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

174

Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management

175

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

176

Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting

177

Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors

178

Breast Cancer — An ASCO 2025 Review

179

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting

180

Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

181

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

182

Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management

183

Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy

184

Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy

185

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

186

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management

187

Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

188

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1

189

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason

190

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu

191

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

192

Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients

193

Biliary Tract Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2

194

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches

195

Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases

196

Ovarian and Endometrial Cancer — An Interview with Dr Shannon Westin on the Current Management Paradigm

197

Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

198

Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma

199

Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations

200

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

201

Multiple Myeloma — Optimizing the Selection of First-Line Therapy

202

Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

203

Gynecologic Cancers — Year in Review Series on Relevant New Datasets and Advances

204

Oncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient Care

205

Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management

206

Soft Tissue Sarcoma and Other Connective Tissue Neoplasms — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting

207

Renal Cell Carcinoma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting

208

Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

209

Oncology Nursing Update: Ovarian Cancer — An Interview with Ms Jennifer Filipi on the Current Treatment Paradigm and New Approaches

210

Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting

211

Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates

212

For Oncology Nurses: Prostate Cancer — Proceedings from the 2025 Annual ONS Congress

213

HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

214

For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress

215

Urothelial Bladder Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

216

Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

217

For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress

218

For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress

219

Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

220

Colorectal Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

221

Ovarian and Endometrial Cancer  — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

222

For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress

223

Prostate Cancer  — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

224

For Oncology Nurses: Ovarian Cancer — Proceedings from the 2025 Annual ONS Congress

225

IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies

226

EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

227

Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 1 of 2

228

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances

229

For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress

230

For Oncology Nurses: Gastroesophageal Cancer — Proceedings from the 2025 Annual ONS Congress

231

Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances

232

Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances

233

For Oncology Nurses: Endometrial Cancer — Proceedings from the 2025 Annual ONS Congress

234

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

235

Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances

236

Prostate Cancer and AKT Inhibitors — Proceedings from a Session Held During the American Urological Association Annual Meeting

237

Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit

238

Hepatocellular Carcinoma — Fourth Annual National General Medical Oncology Summit

239

Multiple Myeloma — Fourth Annual National General Medical Oncology Summit

240

For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2025 Annual ONS Congress

241

Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

242

5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

243

Gastroesophageal Cancer — Fourth Annual National General Medical Oncology Summit

244

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

245

Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies

246

Urothelial Bladder Cancer — Fourth Annual National General Medical Oncology Summit

247

Pancreatic Cancer — Fourth Annual National General Medical Oncology Summit

248

Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies

249

5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

250

Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit

251

Colorectal Cancer — Fourth Annual National General Medical Oncology Summit

252

Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy

253

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

254

Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit

255

Gynecologic Cancers — Fourth Annual National General Medical Oncology Summit

256

Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

257

Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

258

Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances

259

EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit

260

Prostate Cancer — Fourth Annual National General Medical Oncology Summit

261

Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies

262

Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit

263

For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress

264

Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy

265

Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates

266

Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies

267

HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit

268

Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2

269

Ovarian Cancer — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️

270

Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

271

Sarcoma and Other Connective Tissue Neoplasms — Fourth Annual National General Medical Oncology Summit

272

HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit

273

Chronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology Summit

274

Neuroendocrine Tumors — Fourth Annual National General Medical Oncology Summit

275

First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

276

Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates

277

Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent Conferences

278

HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️

279

HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Therapy

280

For Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards

281

5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

282

Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel

283

Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1

284

Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)

285

Colorectal Cancer — Year in Review Series on Relevant New Datasets and Advances

286

Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management

287

Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)

288

5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

289

Biliary Tract Cancers — Reviewing Patient Cases with Prof John Bridgewater: Part 1 of 2

290

Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies

291

Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

292

Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy

293

HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies

294

Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

295

5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

296

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

297

Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani

298

5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

299

Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series

300

Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients

301

Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

302

Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer

303

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

304

Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

305

Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3

306

Chronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

307

Acute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

308

The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2

309

HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1

310

Multiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

311

Chronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

312

Cases from the Community: Integrating New Research Findings into Current Practice — Colorectal and Gastroesophageal Cancers

313

Cases from the Community: Integrating New Research Findings into Current Practice — Hepatobiliary Cancers

314

Cases from the Community: Integrating New Research Findings into Current Practice — Gynecologic Cancers

315

Cases from the Community: Integrating New Research Findings into Current Practice — Myelofibrosis

316

Cases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic Syndromes

317

Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer

318

5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

319

Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review

320

Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer

321

Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria

322

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Multiple Myeloma

323

5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

324

The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences

325

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part Series

326

Optimizing the Management of Tenosynovial Giant Cell Tumor

327

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Prostate Cancer

328

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

329

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

330

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung Cancer

331

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer

332

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

333

Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences

334

The Implications of Recent Datasets for the Current and Future Management of Gastrointestinal Cancers — An ESMO Congress 2024 Review

335

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

336

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma

337

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

338

Practical Perspectives: Current Management of Chronic Myeloid Leukemia

339

The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review

340

Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors

341

Peripheral T-Cell Lymphoma

342

The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer

343

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series

344

The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR

345

The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations

346

Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

347

Striving for Consensus: Optimizing the Current and Future Management of Biliary Tract Cancers

348

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors

349

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers

350

Optimizing the Management of Dedifferentiated Liposarcoma

351

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

352

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

353

Management of Metastatic Urothelial Bladder Cancer

354

Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

355

An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer

356

An interview with Angeles Alvarez Secord, MD, MHSc — Management of Ovarian and Endometrial Cancer

357

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer

358

Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

359

Novel Agents and Strategies in Lung Cancer

360

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma

361

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

362

Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer

363

An interview with Matthew R Smith, MD, PhD — Management of Prostate Cancer

364

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

365

Optimizing the Identification of HER2-Low Breast Cancer

366

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology

367

An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation

368

Investigator Perspectives on Available Research and Challenging Questions in Melanoma and Nonmelanoma Skin Cancers: A Post-ASCO 2024 Annual Review

369

Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma: A Post-ASCO Annual Review

370

RTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal Cancer

371

RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma

372

What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer

373

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis

374

Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer

375

Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer

376

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer

377

Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder Cancer

378

Key Presentations on Lymphoma from Recent Major Conferences

379

Bispecific Antibodies in the Management of Multiple Myeloma

380

Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

381

Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer

382

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia

383

Virtual Case Library: Metastatic Triple-Negative Breast Cancer

384

Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition

385

Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer

386

Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series

387

Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria

388

Special Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers Symposium

389

Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences

390

Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition

391

Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences

392

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer

393

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer

394

The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates

395

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer

396

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma

397

Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer

398

Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review

399

Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer

400

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer

401

Virtual Case Library: Metastatic Urothelial Bladder Cancer

402

Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer

403

Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series

404

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers

405

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia

406

Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers

407

Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part Series

408

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer

409

Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 3 of a 4-Part Series

410

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series

411

Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition

412

Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers

413

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

414

Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 3 of a 3-Part Series

415

Implications of Recent Data Sets for the Current and Future Management of Breast Cancer

416

Implications of Recent Data Sets for the Current and Future Management of Gynecologic Cancers

417

Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 2 of a 3-Part Series

418

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series

419

Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 2 of a 4-Part Series

420

Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer

421

Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 1 of a 3-Part Series

422

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series

423

What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

424

Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences

425

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer

426

Management of Metastatic Pancreatic Cancer with Dr Michael Pishvaian

427

Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

428

Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 of a 4-Part Series

429

What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

430

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer

431

Blastic Plasmacytoid Dendritic Cell Neoplasm

432

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

433

Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma

434

Novel Agents and Strategies in the Treatment of Ovarian Cancer

435

What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors

436

Optimizing the Management of Metastatic Pancreatic Cancer

437

The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma

438

Meet The Professor: Optimizing the Management of Melanoma

439

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

440

The Implications of Recent Data Sets for the Management of Hepatocellular Carcinoma

441

Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer

442

Role of BTK Inhibitors in Therapy for Mantle Cell Lymphoma

443

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series

444

Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences

445

Special Edition — Key Presentations on Genitourinary Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

446

Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor

447

Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management

448

Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

449

Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia

450

Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

451

Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gastrointestinal Cancers Issue

452

Special Edition — Key Presentations on Gynecologic Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

453

Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer — A Clinical Investigator Think Tank

454

Optimizing the Management of Metastatic Urothelial Bladder Cancer

455

Special Edition — Current and Future Management of Breast Cancer

456

Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer Issue

457

Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Colorectal and Gastroesophageal Cancers

458

Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes

459

Immune Thrombocytopenia Edition with Dr Hanny Al-Samkari

460

Paroxysmal Nocturnal Hemoglobinuria Edition with Dr Carlos de Castro

461

Special Edition — Management of Hepatobiliary Cancers

462

Special Edition — Management of Urothelial Bladder Cancer

463

Special Edition — Current and Future Management of Breast Cancer

464

Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder Cancer

465

The Implications of New Research Findings for the Management of Endometrial Cancer

466

Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin Lymphoma

467

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2 - Part Series

468

Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma Edition

469

Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition

470

Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning

471

Management of Desmoid Tumors with Dr Mrinal Gounder

472

Management of HER2-Altered Non-Small Cell Lung Cancer

473

Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation

474

Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting — With Dr Srdan Verstovsek

475

Advances in Diffuse Large B-Cell Lymphoma with Dr Gilles Salles

476

Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting with Dr Richard Stone

477

Special Edition — Management of ER-Positive Breast Cancer with Drs Erica Mayer and Ruth O'Regan

478

HER2-Positive Metastatic Breast Cancer with Professor Giuseppe Curigliano

479

Management of Gastroesophageal Cancers with Dr Manish Shah

480

Managing Metastatic Urothelial Bladder Cancer with Dr Scott Tagawa